Target intelligence / Profile preview

E3 ubiquitin-protein ligase TRIM69 (TRIM69)

Target
TRIM69
Molecular classification
E3 ubiquitin ligase, Tripartite motif-containing protein, Enzyme, Microtubule regulator
01

Overview

E3 ubiquitin-protein ligase TRIM69 (TRIM69) is a member of the tripartite motif (TRIM) family of proteins, characterized by a conserved RING domain, one or two B-box motifs, and a coiled-coil domain structure. TRIM69 functions as both an antiviral effector, particularly in myeloid cells, and a regulator of microtubule stability. It is an interferon-stimulated gene that restricts a broad spectrum of viruses—including HIV-1, HIV-2, SIV, vesicular stomatitis virus, and SARS-CoV-2—by promoting the accumulation of stable microtubules within cells, thereby limiting early phases of viral replication and spread. While TRIM69 possesses E3 ubiquitin ligase activity and can self-ubiquitinate, recent evidence suggests that its antiviral function primarily depends on microtubule stabilization, with the direct cellular substrates and the necessity of E3 ligase activity for this role remaining under investigation. TRIM69 is not currently associated with available drugs, nor is it a known therapeutic biomarker, but as part of the broader TRIM protein family, it is of emerging interest for innate immunity and broad-spectrum antiviral research.

Other names
TRIM69RNF36HSD-34HSD34TrifTRIMLESSRFP-like domain-containing protein trimlessRING finger protein 36ring finger protein 36
02

Mechanism of action

For antiviral action: Promotes the accumulation of stable microtubules, which restricts viral spread in cells—distinct from classical E3 ubiquitin ligase substrate ubiquitination. Mechanism may involve unique cytoskeletal remodeling independent of canonical ubiquitination activity for some functions.

03

Biological functions

Antiviral innate defenseRegulation of microtubule stabilityInterferon-stimulated gene response
04

Disease associations

Infection (broad antiviral effects, e.g. HIV-1, SARS-CoV-2)Other (potentially cancer; general TRIM family involvement, but no direct evidence for TRIM69-specific cancer role)

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase TRIM69 (TRIM69).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM69 (TRIM69).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call